Takeda Forms $1.2 Billion Strategic Partnership with Innovent Biologics

MT Newswires Live10-22

Takeda Pharmaceutical (TAK) said late Tuesday it signed a license and collaboration agreement with Innovent Biologics, covering two of the latter's late-stage oncology medicines.

Takeda will hold the license to develop, manufacture, and commercialize IBI363 and IBI343 globally, except in China, Hong Kong, Macau, and Taiwan, in exchange for a $1.2 billion upfront payment to Innovent Biologics upon closing.

The payment includes a $100 million equity investment in Innovent Biologics, which will also be entitled to additional payments from profit sharing, royalties, and achievement of certain milestones, Takeda said.

Takeda also said the deal grants it an exclusive option to license IBI3001, an early-stage investigational oncology medicine, from Innovent Biologics.

The company said it plans to establish manufacturing for the investigational medicines in the US.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2577517903?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-22 17:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577517903","market":"sg","top_or_hot":-1,"title":"Takeda Forms $1.2 Billion Strategic Partnership with Innovent Biologics","media":"MT Newswires Live","content":"<html><body><p> Takeda Pharmaceutical (TAK) said late Tuesday it signed a license and collaboration agreement with <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics</a>, covering two of the latter's late-stage oncology medicines.</p><p>Takeda will hold the license to develop, manufacture, and commercialize IBI363 and IBI343 globally, except in China, Hong Kong, Macau, and Taiwan, in exchange for a $1.2 billion upfront payment to <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics</a> upon closing.</p><p>The payment includes a $100 million equity investment in Innovent Biologics, which will also be entitled to additional payments from profit sharing, royalties, and achievement of certain milestones, Takeda said.</p><p>Takeda also said the deal grants it an exclusive option to license IBI3001, an early-stage investigational oncology medicine, from Innovent Biologics.</p><p>The company said it plans to establish manufacturing for the investigational medicines in the US.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda Forms $1.2 Billion Strategic Partnership with Innovent Biologics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda Forms $1.2 Billion Strategic Partnership with Innovent Biologics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-22 17:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Takeda Pharmaceutical (TAK) said late Tuesday it signed a license and collaboration agreement with <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics</a>, covering two of the latter's late-stage oncology medicines.</p><p>Takeda will hold the license to develop, manufacture, and commercialize IBI363 and IBI343 globally, except in China, Hong Kong, Macau, and Taiwan, in exchange for a $1.2 billion upfront payment to <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics</a> upon closing.</p><p>The payment includes a $100 million equity investment in Innovent Biologics, which will also be entitled to additional payments from profit sharing, royalties, and achievement of certain milestones, Takeda said.</p><p>Takeda also said the deal grants it an exclusive option to license IBI3001, an early-stage investigational oncology medicine, from Innovent Biologics.</p><p>The company said it plans to establish manufacturing for the investigational medicines in the US.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2577517903","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577517903","pubTimestamp":1761124097,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Takeda Pharmaceutical  said late Tuesday it signed a license and collaboration agreement with Innovent Biologics, covering two of the latter's late-stage oncology medicines.Takeda will hold the license to develop, manufacture, and commercialize IBI363 and IBI343 globally, except in China, Hong Kong, Macau, and Taiwan, in exchange for a $1.2 billion upfront payment to Innovent Biologics upon closing.The payment includes a $100 million equity investment in Innovent Biologics, which will also be entitled to additional payments from profit sharing, royalties, and achievement of certain milestones, Takeda said.Takeda also said the deal grants it an exclusive option to license IBI3001, an early-stage investigational oncology medicine, from Innovent Biologics.The company said it plans to establish manufacturing for the investigational medicines in the US.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","TAK":"武田制药"},"translate_title":"武田与信达生物建立12亿美元战略合作伙伴关系","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":1},"content_text":"Takeda Pharmaceutical (TAK) said late Tuesday it signed a license and collaboration agreement with Innovent Biologics, covering two of the latter's late-stage oncology medicines.Takeda will hold the license to develop, manufacture, and commercialize IBI363 and IBI343 globally, except in China, Hong Kong, Macau, and Taiwan, in exchange for a $1.2 billion upfront payment to Innovent Biologics upon closing.The payment includes a $100 million equity investment in Innovent Biologics, which will also be entitled to additional payments from profit sharing, royalties, and achievement of certain milestones, Takeda said.Takeda also said the deal grants it an exclusive option to license IBI3001, an early-stage investigational oncology medicine, from Innovent Biologics.The company said it plans to establish manufacturing for the investigational medicines in the US.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2577517903","isCrawlerRequest":true}